Internal medicine

Pathology

Receptor

Placebo

Dosing

Angiotensin II

Randomized controlled trial

Alternative medicine

Losartan

Medicine

EClinicalMedicine

The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losartan, may mitigate these effects, though induction of ACE2 could increase viral entry, replication, and worsen disease.

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19